body logic glp-1 Beyond Blood Sugar: A Scoping Review of Receptor Agonists in Cardiovascular Care | Cardiology and Therapy Do GLP-1s cause people to

Orforglipron is a small-molecule oral GLP-1 receptor agonist research compound, while Semaglutide is a peptide-based GLP-1 analog research compound

Continuous monitoring for adverse effects is crucial, given the expanding patient population

Tirzepatide is called a dual incretin because it acts on both GIP and GLP-1 receptors

Compared directly with other second-line antidiabetic medications, semaglutide was again associated with better mental health outcomes, suggesting its benefits extend beyond glucose control alone

Similarly, 33.5% of participants in the combination arm achieved ACR50, compared with 20.4% of those who received ixekizumab alone ( P = .02)